168 related articles for article (PubMed ID: 37042253)
1. Cardioprotective Effect of Empagliflozin and Circulating Ketone Bodies During Acute Myocardial Infarction.
Santos-Gallego CG; Requena-Ibáñez JA; Picatoste B; Fardman B; Ishikawa K; Mazurek R; Pieper M; Sartori S; Rodriguez-Capitán J; Fuster V; Badimon JJ
Circ Cardiovasc Imaging; 2023 Apr; 16(4):e015298. PubMed ID: 37042253
[TBL] [Abstract][Full Text] [Related]
2. Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energetics.
Santos-Gallego CG; Requena-Ibanez JA; San Antonio R; Ishikawa K; Watanabe S; Picatoste B; Flores E; Garcia-Ropero A; Sanz J; Hajjar RJ; Fuster V; Badimon JJ
J Am Coll Cardiol; 2019 Apr; 73(15):1931-1944. PubMed ID: 30999996
[TBL] [Abstract][Full Text] [Related]
3. Empagliflozin Ameliorates Diastolic Dysfunction and Left Ventricular Fibrosis/Stiffness in Nondiabetic Heart Failure: A Multimodality Study.
Santos-Gallego CG; Requena-Ibanez JA; San Antonio R; Garcia-Ropero A; Ishikawa K; Watanabe S; Picatoste B; Vargas-Delgado AP; Flores-Umanzor EJ; Sanz J; Fuster V; Badimon JJ
JACC Cardiovasc Imaging; 2021 Feb; 14(2):393-407. PubMed ID: 33129742
[TBL] [Abstract][Full Text] [Related]
4. Sodium-glucose co-transporter 2 inhibition with empagliflozin improves cardiac function in non-diabetic rats with left ventricular dysfunction after myocardial infarction.
Yurista SR; Silljé HHW; Oberdorf-Maass SU; Schouten EM; Pavez Giani MG; Hillebrands JL; van Goor H; van Veldhuisen DJ; de Boer RA; Westenbrink BD
Eur J Heart Fail; 2019 Jul; 21(7):862-873. PubMed ID: 31033127
[TBL] [Abstract][Full Text] [Related]
5. Load-independent effects of empagliflozin contribute to improved cardiac function in experimental heart failure with reduced ejection fraction.
Connelly KA; Zhang Y; Desjardins JF; Nghiem L; Visram A; Batchu SN; Yerra VG; Kabir G; Thai K; Advani A; Gilbert RE
Cardiovasc Diabetol; 2020 Feb; 19(1):13. PubMed ID: 32035482
[TBL] [Abstract][Full Text] [Related]
6. Ketone body levels and its associations with cardiac markers following an acute myocardial infarction: a post hoc analysis of the EMMY trial.
Aziz F; Tripolt NJ; Pferschy PN; Scharnagl H; Abdellatif M; Oulhaj A; Benedikt M; Kolesnik E; von Lewinski D; Sourij H
Cardiovasc Diabetol; 2024 Apr; 23(1):145. PubMed ID: 38678253
[TBL] [Abstract][Full Text] [Related]
7. Sphingosine-1-Phosphate Receptor Agonist Fingolimod Increases Myocardial Salvage and Decreases Adverse Postinfarction Left Ventricular Remodeling in a Porcine Model of Ischemia/Reperfusion.
Santos-Gallego CG; Vahl TP; Goliasch G; Picatoste B; Arias T; Ishikawa K; Njerve IU; Sanz J; Narula J; Sengupta PP; Hajjar RJ; Fuster V; Badimon JJ
Circulation; 2016 Mar; 133(10):954-66. PubMed ID: 26826180
[TBL] [Abstract][Full Text] [Related]
8. Assessment of Cardiac Energy Metabolism, Function, and Physiology in Patients With Heart Failure Taking Empagliflozin: The Randomized, Controlled EMPA-VISION Trial.
Hundertmark MJ; Adler A; Antoniades C; Coleman R; Griffin JL; Holman RR; Lamlum H; Lee J; Massey D; Miller JJJJ; Milton JE; Monga S; Mózes FE; Nazeer A; Raman B; Rider O; Rodgers CT; Valkovič L; Wicks E; Mahmod M; Neubauer S
Circulation; 2023 May; 147(22):1654-1669. PubMed ID: 37070436
[TBL] [Abstract][Full Text] [Related]
9. Effect of empagliflozin on ketone bodies in patients with stable chronic heart failure.
Pietschner R; Kolwelter J; Bosch A; Striepe K; Jung S; Kannenkeril D; Ott C; Schiffer M; Achenbach S; Schmieder RE
Cardiovasc Diabetol; 2021 Nov; 20(1):219. PubMed ID: 34753480
[TBL] [Abstract][Full Text] [Related]
10. Acute SGLT-2i treatment improves cardiac efficiency during myocardial ischemia independent of Na
Baker HE; Tune JD; Mather KJ; Blaettner BS; Clark HE; Li F; Li X; Kowala MC; Fliegel L; Goodwill AG
Int J Cardiol; 2022 Sep; 363():138-148. PubMed ID: 35753619
[TBL] [Abstract][Full Text] [Related]
11. Bone marrow-derived naïve B lymphocytes improve heart function after myocardial infarction: a novel cardioprotective mechanism for empagliflozin.
Xu Y; Jiang K; Chen F; Qian J; Wang D; Wu Y; Zhou C; Yu Y; Chen K; Hwa J; Yang B; Wang H; Xiang Y
Basic Res Cardiol; 2022 Sep; 117(1):47. PubMed ID: 36171393
[TBL] [Abstract][Full Text] [Related]
12. Mechanically unloading the left ventricle before coronary reperfusion reduces left ventricular wall stress and myocardial infarct size.
Kapur NK; Paruchuri V; Urbano-Morales JA; Mackey EE; Daly GH; Qiao X; Pandian N; Perides G; Karas RH
Circulation; 2013 Jul; 128(4):328-36. PubMed ID: 23766351
[TBL] [Abstract][Full Text] [Related]
13. Ketone Ester Treatment Improves Cardiac Function and Reduces Pathologic Remodeling in Preclinical Models of Heart Failure.
Yurista SR; Matsuura TR; Silljé HHW; Nijholt KT; McDaid KS; Shewale SV; Leone TC; Newman JC; Verdin E; van Veldhuisen DJ; de Boer RA; Kelly DP; Westenbrink BD
Circ Heart Fail; 2021 Jan; 14(1):e007684. PubMed ID: 33356362
[TBL] [Abstract][Full Text] [Related]
14. Correlation between myocardial strain and adverse remodeling in a non-diabetic model of heart failure following empagliflozin therapy.
Garcia-Ropero A; Santos-Gallego CG; Vargas-Delgado AP; Requena-Ibanez JA; Picatoste B; Ishikawa K; Sanz J; Tunon J; Badimon JJ
Expert Rev Cardiovasc Ther; 2020 Sep; 18(9):635-642. PubMed ID: 32713221
[TBL] [Abstract][Full Text] [Related]
15. Impact of EMpagliflozin on cardiac function and biomarkers of heart failure in patients with acute MYocardial infarction-The EMMY trial.
Tripolt NJ; Kolesnik E; Pferschy PN; Verheyen N; Ablasser K; Sailer S; Alber H; Berger R; Kaulfersch C; Leitner K; Lichtenauer M; Mader A; Moertl D; Oulhaj A; Reiter C; Rieder T; Saely CH; Siller-Matula J; Weidinger F; Zechner PM; von Lewinski D; Sourij H;
Am Heart J; 2020 Mar; 221():39-47. PubMed ID: 31901799
[TBL] [Abstract][Full Text] [Related]
16. Empagliflozin prevents from early cardiac injury post myocardial infarction in non-diabetic mice.
Liu Y; Wu M; Xu J; Xu B; Kang L
Eur J Pharm Sci; 2021 Jun; 161():105788. PubMed ID: 33684486
[TBL] [Abstract][Full Text] [Related]
17. Ketone ester supplementation suppresses cardiac inflammation and improves cardiac energetics in a swine model of acute myocardial infarction.
Yurista SR; Eder RA; Welsh A; Jiang W; Chen S; Foster AN; Mauskapf A; Tang WHW; Hucker WJ; Coll-Font J; Rosenzweig A; Nguyen CT
Metabolism; 2023 Aug; 145():155608. PubMed ID: 37268056
[TBL] [Abstract][Full Text] [Related]
18. Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF).
Lee MMY; Brooksbank KJM; Wetherall K; Mangion K; Roditi G; Campbell RT; Berry C; Chong V; Coyle L; Docherty KF; Dreisbach JG; Labinjoh C; Lang NN; Lennie V; McConnachie A; Murphy CL; Petrie CJ; Petrie JR; Speirits IA; Sourbron S; Welsh P; Woodward R; Radjenovic A; Mark PB; McMurray JJV; Jhund PS; Petrie MC; Sattar N
Circulation; 2021 Feb; 143(6):516-525. PubMed ID: 33186500
[TBL] [Abstract][Full Text] [Related]
19. Associations of Empagliflozin With Left Ventricular Volumes, Mass, and Function in Patients With Heart Failure and Reduced Ejection Fraction: A Substudy of the Empire HF Randomized Clinical Trial.
Omar M; Jensen J; Ali M; Frederiksen PH; Kistorp C; Videbæk L; Poulsen MK; Tuxen CD; Möller S; Gustafsson F; Køber L; Schou M; Møller JE
JAMA Cardiol; 2021 Jul; 6(7):836-840. PubMed ID: 33404637
[TBL] [Abstract][Full Text] [Related]
20. Empagliflozin, an SGLT2 Inhibitor, Reduced the Mortality Rate after Acute Myocardial Infarction with Modification of Cardiac Metabolomes and Antioxidants in Diabetic Rats.
Oshima H; Miki T; Kuno A; Mizuno M; Sato T; Tanno M; Yano T; Nakata K; Kimura Y; Abe K; Ohwada W; Miura T
J Pharmacol Exp Ther; 2019 Mar; 368(3):524-534. PubMed ID: 30552292
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
